Skip to main content

Research & development of rectal artesunate (ARTESUNATE)

Objective

The proposal is to complete the chemical development, efficacy and safety evaluation of an ant malarial articulate, which has not yet been registered for use in the EU or US. The intended beneficiary is a patient living in or travelling to a malaria endemic country. The drug is being developed to provide therapeutic cover for patients with severe disease, who can no longer take drugs by mouth, and who cannot access inject able treatment, until they can reach facilities where definitive therapy can be provided. Costs cover completion of the chemical development, proof of bio equivalence, and clinical trials to establish efficacy of the GMP product and its safety.

Funding Scheme

DEM - Demonstration contracts

Coordinator

EURO HEALTH GROUP
Address
Tinghojvej 77
2860 Soeborg
Denmark

Participants (7)

KNOLL AG
Switzerland
Address
Oristalstrasse 65
4410 Liestal
MAHIDOL UNIVERSITY
Thailand
Address
420,Rajvithi Road 42/46
1400 Bangkok
MINISTRY OF HEALTH - GHANA
Ghana
Address

10 Navrongo
R P SCHERER GMBH & CO. KG
Germany
Address
Eberbach Baden
69402 Eberbach
SCANPHARM S/A
Denmark
Address
Topstykket, 12
3460 Birkerod
UNIVERSITY OF CAPE TOWN
South Africa
Address
Old Main Building K 435, Groote Schuur Hospital Ob
Cape Town
WORLD HEALTH ORGANIZATION
Switzerland
Address
Avenue Appia 20
1211 Geneve